Login to Access Video or Poster Abstract: MP73-03
Sources of Funding: none

Introduction

Programmed death ligand-1 (PD-L1), as a promising anti-tumor target, has proved its significant clinical value in many malignancies. However, the expression of PD-L1 in Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and association with clinical outcomes remains unclear. This study amid to investigate the expression of PD-L1 in Xp11.2 RCC and to assess its prognostic value.

Methods

Immunohistochemistry was conducted on formalin-fixed paraffin-embedded specimens from 36 adult Xp11.2 RCC patients who were histologically confirmed by FISH analysis. Students’s t-test and Chi-square test were used to evaluate the relationship between PD-L1 expression and clinicopathological parameters. Cox regression models were used to evaluate the prognostic value of all parameters.

Results

Among 36 assessed Xp11.2 RCC patients, 9 (25.0%) patients showed high expression of PD-L1 and 27 (75.0%) patients showed low PD-L1 expression. High PD-L1 expression was correlated with the presence of advanced tumor stage (P=0.001), regional lymph node metastasis (P<0.001) and distant metastasis (P<0.001). In the multivariate analysis, N stage (HR: 4.316, P = 0.032), M stage (HR: 16.561, P = 0.009) and high PD-L1 expression (HR: 4.236, P = 0.007) were independent prognostic factors of PFS. Moreover, high PD-L1 expression (HR: 6.479, P = 0.006), along with distant metastasis (HR: 9.215, P = 0.016), was independent prognostic factors after adjusting for covariates.

Conclusions

High PD-L1 expression is independently associated with tumor progression and predictive of adverse prognosis for Xp11.2 RCC patients. Importantly, our findings may provide a basis for the use of immunotherapy targeting the PD-1/PD-L1 pathway as a potential novel treatment for Xp11.2 RCC patients.

Funding

none